The Fast Track drug development program is designed to promote the development of drugs to treat life-threatening or very serious conditions and requires that the drug demonstrate the potential to address unmet medical needs.
Ulrich Grau, president and CEO of Lux, said: “With this Fast Track designation, we can more rapidly work to provide a much needed therapy to patients. If successful, LX201 would become the first treatment available for the prevention of corneal transplant rejection.”